Emergent BioSolutions Earnings Estimates, EPS & Revenue | NYSE:EBS

Comments

Emergent BioSolutions Inc Earnings Estimates

EBSNYSE

Trade with Public

$8.66

0.425.10%

At close: Apr 14, 5:00 PM EST

$8.66

N/A

After Hours: 4:00 PM EST

Overview NewsEarningsOptions Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Emergent BioSolutions Earnings Estimates, EPS & Revenue | NYSE:EBS

Emergent BioSolutions (EBS) is scheduled to report Q1 earnings on May 6, 2026. Analysts estimate EPS of $-0.05 and quarterly revenue of $160.50M.

In the most recent quarter (Q4), Emergent BioSolutions reported EPS of $-0.43, missing estimates of $0.32 by 2.34%. Revenue came in at $148.70M, missing the estimate of $216.50M by 0.31%.

Over the last 4 quarters, Emergent BioSolutions has averaged an EPS surprise of 10.17% and a revenue surprise of 0.19%.

Earnings Date

May 6

EPS Estimate

$-0.050

Quarterly Revenue Estimate

$160.50M

Annual Revenue
(as of Dec 31)

$705.20M

Emergent BioSolutions Earnings History

Analyze the earnings history of Emergent BioSolutions using advanced sorting and filters.

Loading calendar...

Emergent BioSolutions (EBS) Earnings Per Share

The chart below shows Emergent BioSolutions's reported EPS compared to analyst estimates over recent quarters.

Emergent BioSolutions (EBS) Revenue

The chart below shows Emergent BioSolutions's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Emergent BioSolutions (NYSE:EBS) reporting earnings?

Emergent BioSolutions (EBS) is scheduled to report earnings on May 6, 2026. The last reported earnings were for reported on February 26, 2026 for Q4.

What were the latest earnings per share (EPS) for Emergent BioSolutions (NYSE:EBS)?

The Actual EPS was $-0.43, which missed the estimate of $0.32.

What were Emergent BioSolutions’s (NYSE:EBS) revenues?

The Actual Revenue was $148.70M, which missed the estimate of $216.50M.

People Also Watch

Zentalis Pharmaceuticals Inc

ARMP

Eupraxia Pharmaceuticals Inc

Century Therapeutics Inc

NASDAQ:IPSC

$2.37

Lexeo Therapeutics Inc

NASDAQ:LXEO

$6.80

1.91%

Emergent BioSolutions Earnings Estimates, EPS & Revenue | NYSE:EBS

Emergent BioSolutions (EBS) is scheduled to report Q1 earnings on May 6, 2026. Analysts estimate EPS of $-0.05 and quarterly revenue of $160.50M.

In the most recent quarter (Q4), Emergent BioSolutions reported EPS of $-0.43, missing estimates of $0.32 by 2.34%. Revenue came in at $148.70M, missing the estimate of $216.50M by 0.31%.

Over the last 4 quarters, Emergent BioSolutions has averaged an EPS surprise of 10.17% and a revenue surprise of 0.19%.

Earnings Date

May 6

EPS Estimate

$-0.050

Quarterly Revenue Estimate

$160.50M

Annual Revenue
(as of Dec 31)

$705.20M